USFDA approves next-gen TKI Augtyro for treatment of solid tumors
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
New software solution helps manufacturers digitalize and gain insights from data to increase efficiency
This strategic decision will unlock significant value for our scientific and industrial products business
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
Subscribe To Our Newsletter & Stay Updated